In this week’s Psychedelic news roundup, we discuss two new African psilocybe species, detail advancements in synthetic psychedelics, a rapid shift in American interest in DMT, and more.

New Hallucinogenic Mushrooms Discovered in Southern Africa: A Leap in Psychedelic Research

New Mushroom Species

As reported by Newsweek, a groundbreaking discovery has expanded our understanding of psychedelic flora. Scientists have identified two new species of hallucinogenic mushrooms in southern Africa, Psilocybe ingeli and Psilocybe maluti. This finding, detailed in a recent publication in Mycologia, highlights the region’s rich biodiversity and the potential for new research into the psychoactive properties of these fungi.

Key Discoveries:

  • New Species Identified: Psilocybe ingeli and Psilocybe maluti are the latest additions to the Psilocybe genus.
  • Unique Characteristics: These mushrooms differ significantly from their closest known relatives due to their diminutive size and the distinct shape of the cap. Thus, there are now six known psilocybe species native to Africa.
  • Psychoactive Properties: Like their genus counterparts, these mushrooms contain psilocybin, making them of particular interest both scientifically and culturally.

Research and Implications:

  • Citizen Science Contributions: The discovery was facilitated by the contributions of citizen scientists in South Africa, who provided specimens for genetic analysis that confirmed the new species.
  • Cultural Significance: While new to Western science, in the Kingdom of Lesotho, Psilocybe maluti is traditionally used by Basotho healers to induce trance-like states, highlighting the spiritual and medicinal applications of these mushrooms.
  • Potential for Further Discovery: The researchers emphasize the likelihood of more undiscovered Psilocybe species in southern Africa and advocate for increased citizen scientist involvement in mycological research.

The article’s authors believe this discovery enhances our knowledge of unique biological systems and highlights the critical role of regional biodiversity in unraveling global ecological patterns and the therapeutic potential of psychedelic compounds.(1)

Massachusetts to Vote on Psychedelics Legalization in November

Psychedelics Legalization Voting

As reported by Marijuana Moment, Massachusetts voters are set to make a significant decision this November on whether to legalize certain psychedelic substances. The measure, aimed at addressing a range of mental health conditions, will appear on the ballot after successful petitioning by the campaign group Massachusetts for Mental Health Options (MMHO). Secretary of the Commonwealth William F. Galvin confirmed that activists had gathered sufficient signatures to advance the proposal.

Key Points of the Initiative:

  • Eligibility: Adults aged 21 and over would be allowed to possess, grow, and share specified amounts of psychedelics.
  • Substances and Limits: The initiative covers DMT (one gram), non-peyote mescaline (18 grams), ibogaine (30 grams), psilocybin (one gram), and psilocin (one gram). These limits exclude any material that contains the active substances.
  • Penalties: Possessing up to double the specified limits would incur a $100 civil fine. Possessing higher amounts would remain a criminal offense.
  • Regulatory Body: A new Natural Psychedelic Substances Commission would oversee the law’s implementation and license service centers and facilitators.
  • Taxation: Psychedelics sold at licensed facilities would charge a 15% excise tax, with an optional additional 2% tax for localities permitting these centers.
  • Usage Spaces: Individuals could cultivate psychedelics in an area no larger than 12×12 ft.

The proposal has faced skepticism despite the enthusiasm from advocates like Emily Oneschuk, a veteran and the nation’s first female Navy Seals candidate, who emphasized the potential benefits for veterans and other residents. A recent report from the legislature’s Special Joint Committee on Ballot Initiatives recommended against the measure, questioning the safety and benefits of widespread recreational legalization. The committee expressed concerns about creating dual systems for psychedelic use—one through regulated service centers and another through broader decriminalization.

As Massachusetts prepares for the November vote, the outcome could pave the way for significant changes in how psychedelics are accessed and used, potentially influencing broader national discussions on drug policy reform. The decision remains contentious, reflecting deep divides on the best approaches to integrate such substances into society legally and safely.(2)

Could Synthetic Psilocybin be an Effective Depression Treatment?

Compass logo

Forbes details a new psychedelic tool for the treatment of certain types of depression. The battle against treatment-resistant depression (TRD) has long been a tough one, with many individuals struggling to find relief through traditional methods such as antidepressants, talk therapy, and alternative treatments. However, recent advancements in synthetic psychedelic research may hold a solution if proven effective.

About COMP360 Synthetic Psilocybin:

  • Synthetic Origin: Known as COMP360 (and developed by Compass Pathways), this laboratory-created psilocybin adheres to FDA standards for safety and consistency.
  • Initial Results: In a comprehensive study involving 233 participants, COMP360 demonstrated promising outcomes—about 30% of patients achieved remission by the third week after a single 25 mg dose. The effects appeared rapid and enduring, with sustained responses observed until the 12th week. However, more research is needed.

Understanding the Treatment:

  • Neuroplasticity: COMP360 targets specific serotonin receptors in the brain, which may foster neuroplasticity or the brain’s ability to form new neural connections.
  • Treatment Protocol: Like other clinical psychedelics such as MDMA, COMP360’s administration is carefully controlled, involving extensive therapist training and rigorous session monitoring to ensure adherence to therapeutic standards and protocols.

Current Research and Safety Measures:

  • Ongoing Study: Following the initial successful trial, further research is needed to validate the long-term efficacy and safety of COMP360 psilocybin. This phase includes tighter controls over therapeutic practices to ensure consistent and ethical treatment delivery.

By focusing on the brain’s adaptability and addressing depression at a neurological level, researchers are optimistic about providing new hope for those who have found little relief with existing treatments.(3)

DMT Tops American Psychedelic Curiosity Over Shrooms and Marijuana

DMT Tops American Psychedelic Curiosity

Phoenix New Times covers the rise of a surprising psychedelic darling capturing America’s imagination. Despite the legality of marijuana in many states, including Arizona since 2020, and the growing interest in psilocybin mushrooms with ongoing studies and decriminalization efforts, Americans are most curious about another psychedelic: DMT (dimethyltryptamine). This compound, which is also present in the South American brew ayahuasca (made from the Banisteriopsis caapi vine boiled with the leaves of the Psychotria viridis shrub), is now the leading subject of psychedelic-related searches in the U.S., according to a new study by SporesMD.

Key Insights:

  • Most Searched Psychedelic: DMT has surpassed other psychedelics in online searches, indicating a significant shift in American interest in this powerful psychedelic substance.
  • Intense Effects: Known for its rapid onset and short duration, DMT provides a condensed, intense visual and auditory hallucinogenic experience, often referred to as “the businessman’s trip” due to its brief effects.
  • Cultural and Legal Status: DMT is sacred in traditional spiritual ceremonies, particularly in South America. Despite its classification as a Schedule 1 drug in the U.S., making recreational use illegal, courts have recognized DMT and ayahuasca use in religious contexts, allowing for legal exemptions.

This surge in interest likely stems from DMT’s unique psychedelic profile. Some research suggests DMT is a naturally occurring substance in several plant species and possibly the human body. Its effects are profound, offering a rapid onset of hallucinations filled with vibrant colors and geometric patterns, lasting about 15 to 30 minutes when smoked or vaped—much shorter than LSD or psilocybin experiences. These characteristics contribute to its mystique and the growing intrigue around its therapeutic potential and spiritual significance, drawing attention beyond traditional psychedelic communities to a broader audience seeking profound, time-efficient transformative experiences.(4)

This material is not intended as a replacement or substitute for any legal or medical advice. Always consult a medical professional about your health needs. Psychedelics are widely illegal in the United States, and readers should always be informed about local, state, and federal regulations regarding psychedelics or other drugs.


  1. Science, A. G., & Reporter, H. (2024, July 8). Scientists discover two new species of hallucinogenic mushroom. Newsweek. https://www.newsweek.com/scientists-discover-two-new-species-hallucinogenic-mushroom-1922228 
  2. Jaeger, K. (2024, July 11). Massachusetts Voters Will Decide On Psychedelics Legalization Initiative On November Ballot, State Announces. Marijuana Moment. https://www.marijuanamoment.net/massachusetts-voters-will-decide-on-psychedelics-legalization-initiative-on-november-ballot-state-announces/ 
  3. Travers, M. (n.d.). A Synthetic Psychedelic Is Making Waves In Stubborn Depression Treatment—Here’s What You Need To Know. Forbes. Retrieved July 11, 2024, from https://www.forbes.com/sites/traversmark/2024/07/08/a-synthetic-psychedelic-is-making-waves-in-stubborn-depression-treatment-heres-what-you-need-to-know/ 
  4. Buchanan, Z. (n.d.). Move over, shrooms: Americans are most curious about this psychedelic. Phoenix New Times. Retrieved July 11, 2024, from https://www.phoenixnewtimes.com/marijuana/americans-more-curious-about-dmt-than-other-psychedelic-drugs-study-19419042